Rac1 Pharmacological Inhibition Rescues Human Endothelial Dysfunction

Area of Science:

• Vascular Biology
• Pharmacology
• Oxidative Stress

Background:

• Endothelial dysfunction is a key factor in vascular disease development.
• Current therapies for endothelial dysfunction are limited.
• Rac1, a small GTPase, promotes oxidative stress and contributes to endothelial dysfunction.

Purpose of the Study:

• To investigate the therapeutic potential of Rac1 inhibition in human endothelial dysfunction.
• To evaluate the effects of NSC23766, a Rac1 inhibitor, on endothelial function in human saphenous veins.

Main Methods:

• Vascular reactivity studies were conducted on saphenous vein segments from patients with venous insufficiency and peripheral vascular surgery.
• Measurements included endothelium-dependent vasorelaxation, Rac1 activity, reactive oxygen species (ROS) levels, and NADPH oxidase activity.
• The effects of NSC23766 were assessed in both varicose and non-varicose vein segments.

Main Results:

• Varicose veins exhibited impaired endothelium-dependent vasorelaxation, increased Rac1 activity, ROS, and NADPH oxidase activity compared to control veins.
• Treatment with NSC23766 significantly improved vasorelaxation in dysfunctional veins via a nitric oxide-dependent pathway.
• Rac1 inhibition reduced NADPH oxidase activity and enhanced endothelial nitric oxide synthase (eNOS) activation, improving venous endothelial function.

Conclusions:

• Pharmacological inhibition of Rac1 effectively rescues endothelial function in dysfunctional veins.
• Rac1 inhibition reduces oxidative stress markers, including NADPH oxidase activity.
• Targeting Rac1 represents a promising therapeutic strategy for endothelial dysfunction and associated vascular diseases.